Platelet aggregation inhibitors in prevention and treatment of coronary thrombosis.
Platelet aggregation plays a key role in the development of complications of atherosclerosis. By inhibiting platelet aggregation in a pharmacological way complications such as myocardial infarction and sudden death may be prevented. This goes for primary as well as secondary prevention. The most relevant substances for this goal are aspirin, clopidogrel and the new glycoprotein IIb/IIIa inhibitors.
Gomes
M E R
ME
Department of Cardiology (540), Heart Centre, University Medical Centre, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands.
Verheugt
F W A
FW
D003328:Coronary Thrombosis / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors